Skip to main content
Fig. 5 | Retrovirology

Fig. 5

From: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Fig. 5

HIV DNA in peripheral blood. HIV DNA medians for each group are shown from M0 to M12. Volunteers with undetectable HIV DNA (<20 copies/106 PBMC) were counted as having respectively 19 copies, which is 1.3 log copies/ml (dashed line). The placebo group is depicted as a black square, the 11 µg group as a black circle, the 33 µg group as a white square and the 99 µg group as a white circle. Median decreases in HIVDNA levels were observed at doses of 99 µg (n = 10) from 1.8 (TR 1.3–2.5) to 1.3 (TR 1.3–2.6) log copies HIV DNA/106 PBMC between M0 and M4 and is due to six volunteers with HIV DNA copies <20. The absence of HIVDNA rebound at M6 with the 33 µg group is highly significant in a Mann and Whitney test (p = 0.001). At M12, the 33 µg group has a median of 1.4 log copies/ml that is very close of the undetectable level. However, this difference is not significant (p > 0.1) compared to M0

Back to article page